Effects of edible algae polysaccharides on allergic, inflammatory, and anti-tumor responses through toll-like receptor 4

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 9, Issue 3, 2010, Pages 238-250

  Tominaga, Akira ^a,d   Okuyama, Hiromi ^b   Fukuoka, Satoshi ^c   Taguchi, Takahiro ^a   Kusumoto, Yutaka ^b   Shimizu, Keiji ^d   Ono, Shiro ^b  

^a Graduate School of Kuroshio Science   (Japan)

^b OSAKA OHTANI UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d KOCHI UNIVERSITY   (Japan)

Author keywords

Algae; Allergic responses; IL 17; Inflammation; Polysaccharide; TLR; Tumor

Indexed keywords

ALGINIC ACID; FUCOIDIN; GAMMA INTERFERON; HEPARAN SULFATE; HEPARIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 23; POLYSACCHARIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ALGA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; PETALONIA BINGHAMIAE; PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; SPIRULINA PACIFICA; TH17 CELL; TUMOR MICROENVIRONMENT;

EID: 77958505891     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871523011009030238     Document Type: Article

References (86)

1. Medzithov, R.; Janeway, Jr, C. A. Innate Immunity: The virtues of a nonclonal system of recognition. Cell, 1997, 91, 295-8.
2. Akira, S.; Takeda, K.; Kaisho, T. Nat. Immunol., 2001, 2, 675-80. Toll-like receptors: critical proteins linking innate and aquired immunity.
3. Rodríguez, D.; Keller, A. C.; Faquim-Mauro, E. L.; de Macedo, M. S.; Cunha, F. Q.; Lefort, J.; Vargaftig, B. B.; Russo, M. Bacterial lipopolysaccharide signaling through toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity. J. Immunol., 2003, 171, 1001-8.
4. Revets, H.; Pynaert, G.; Grooten, J.; De Baetselier, P. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J. Immunol., 2005, 174, 1097-03.
5. Mosmann, T. R.; Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 1989, 7, 145-73.
6. Weaver, C. T.; Harrington, L. E.; Mangan, P. R.; Gavrieli, M.; Murphy, K. M. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity, 2006, 24, 677-88.
7. Dong, C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol., 2008, 8, 337-48.
8. Weaver, C. T.; Hatton, R. D.; Mangan, P. R.; Harrington, L. E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol., 2007, 25, 821-52.
9. Kastelein, R. A.; Hunter, C. A.; Cua, D. J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators in inflammation. Annu. Rev. Immunol., 2007, 25, 221-42.
10. Korn, T.; Bettelli, E.; Oukka, M.; Kuchroo, V. K. IL-17 and Th17 cells. Annu. Rev. Immunol., 2009, 27, 485-517.
11. Ishigame, H.; Kakuta, S.; Nagi, T.; Kadoki, M.; Nambu, A.; Komiyama, Y.; Fujikado, N.; Tanahashi, Y.; Akitsu, A.; Kotaki, H., Sudo, K.; Nakae, S.; Sasakawa, C.; Iwakura, Y. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity, 2009, 30, 108-19.
12. Rouvier, E.; Luciani, M. F.; Mattéi, M. G.; Denizot, F.; Golstein, P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol., 1993, 150, 5445-56.
13. Ivanov, II; McKenzie, B. S.; Zhou, L.; Tadokoro, C. E.; Lepelley, A.; Lafaille, J. J.; Cua, D. J.; Littman, D. R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T cells. Cell, 2006, 126, 1121-33.
14. Kolls, J. K.; Lindén, A. Interleukin-17 family members and inflammation. Immunity, 2004, 21, 467-76.
15. Gaffen, S. L. Structure and signaling in the IL-17 receptor family. Nat. Rev. Immunol., 2009, 9, 556-67.
16. Lin, Y.; Ritchea, S.; Logar, A.; Slight, S.; Messmer, M.; Rangel-Moreno, J.; Guglani, L.; Alcorn, J. F.; Strawbridge, H., Park, S. M.; Onishi, R.; Nyugen, N.; Walter, M. J.; Pociask, D.; Randall, T. D.; Gaffen, S. L.; Iwakura, Y.; Kolls, J. K.; Khadar, S. A. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity, 2009, 31, 799-810.
17. Murphy, C. A.; Langrish, C. L.; Chen, Y.; Blumenschein, W.; McClanahan, T.; Kastelein, R. A.; Sedgwick, J. D.; Cua, D. J. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med., 2003, 198, 1951-7.
18. Numasaki, M.; Fukushi, J.-I.; Ono, M.; Narula, S. K.; Zavondny, P.J.; Kudo, T.; Robbins, P. D.; Tahara, H.; Lotze, M. T. Interleukin-17 promotes angiogenesis and growth. Blood, 2003, 101, 2620-27.
19. Zhu, X. W.; Mulcahy, L.A.; Mohammed R. AA.; Lee, A. HS.; Franks, H. A.; Kilpatrick, L.; Yilmazar, A.; Paish, E. C.; Ellis, I. O.; Patel P. M.; Jackson, A. M. IL-17 expression by breast-cancer associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res., 2008, 10, R95.
20. Cohn, L.; Herrick, C.; Niu, N.; Homer, R.; Bottomly, K. IL-4 promotes airway eosinophilia by suppressing IFN-gamma production: defining a novel role for IFN-gamma in the regulation of allergic airway inflammation. J. Immunol., 2001, 166, 2760-7.
21. Huang, T.; MacAry, J.P.A.; Eynott, P.; Moussavi, A.; Daniel, K. C.; Askenase, P. W.; Kemeny, D. M.; Chung, K.F. Allergenspecific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFNgamma. J. Immunol., 2001, 166, 207-17.
22. Karin, M. Nuclear factor-??B incancer development and progression. Nature, 2006, 441, 431-6.
23. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell, 2006, 124, 783-801.
24. Karin, M.; Lawrence, T.; Nizet, V. Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell, 2006, 124, 823-35.
25. Delude, R. L.; Yoshimura, A.; Ingalls, R. R.; Golenbock, D. T. Construction of a lipopolysaccharide receptor cell line and its use inidentifying mutants defective inendotoxin, but not TNF-??, signal transduction. J. Immunol., 1998, 161, 3001-9.
26. Medvedev, A. E.; Henneke, P.; Schromm, A.; Lien, E.; Ingalls, R.; Fenton, M. J.; Golenbock, D. T.; Vogel, S. N. Induction of tolerance to lipopolysaccharide and Mycobacterial components in Chinese hamster ovary /CD14 cells is not affected by overexpression of toll-like receptors 2 or 4. J. Immunol., 2001, 2257-67.
27. Satoh, T.; Chen, Q.J.; Sasaki, G.; Yokozeki, H. Katayama, Nishioka, K. Cyclophosphamide-induced blood and tissue eosinophilia in contact sensitivity: mechanism of hapten-induced eosinophil recruitment into the skin. Eur. J. Immunol. 1997, 27, 85-91.
28. Poltorak, A.; Xiaolong, He.; Smirnova, I.; Liu, Mu-Ya, Van Huffel, C.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Ricciardi-Castagnoli, P.; Layton, B.; Beutler, B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutastions in Tlr4 gene. Science, 1998, 282, 2085-8, 1998.
29. Yusuf, N.; Nasti, T. H.; Long, A.; Naseemuddin, M.; Lucas, A. P.; Xu, H.; Elmets, C. A. Protective role of toll-like receptor 4 during the initiation stage cutaneous chemical carcinogenesis. Cancer Res., 2008, 68, 615-22.
30. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
31. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420, 860-7.
32. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454, 436-44.
33. Colotta, F.; Allavena, P.; Sica, A., Garlanda, C., Mantovani, A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 2009, 30, 1073-81.
34. Dighe, A. S.; Richards, E.; Old, L. J.; Schreiber, R. D. Enhanced in vivo growth and registance to rejection of tumor cells expressing dominant negative IFN?? receptors. Immunity, 1994, 1, 447-56.
35. Nakajima, C.; Uekusa, Y.; Iwasaki, M.; Yamaguchi, N.; Mukai, T.; Gao, P.; Tomura, M.; Ono, S.; Tsujimura, T.; Fujiwara, H.; Hamaoka, T. A role of interferon-g (IFN-??) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-??-deficient mice. Cancer Res., 2001, 61, 3399-405.
36. Shankaran, V.; Ikeda, H.; Bruce, A. T.; White, J.M.; Swanson, P.E.; Old, L.J.; Schreiber, R.D. IFN?? and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410, 1107-11.
37. Dalton, D. K.; Pitts-Meek, S.; Keshav, S.; Figari, I. S.; Bradley, A.; Stewart, T. A. Multiple defects of immune cell function in mice with disrupted interferon-?? genes. Science, 1993, 259, 1739-42
38. Mizuno, D.-I.; Yoshioka O.; Akamatu, M.; Kataoka T. Antitumor effect of intracutaneous injection of bacterial lipopolysaccharide. Cancer Res, 1968, 28: 1531-7.
39. Ohnishi, M., Kimura, S., Yamazaki, M., Oshima, H., Mizuno, D.- I., Abe, S., Yamaguchi, H. Anti-tumor activity of low-toxicity lipopolysaccharide of Bordetella pertusis. Br. J. Cancer, 1994, 69,1038-42.
40. Westphal, O.; Jann, K. Bacterial lipopolysaccharides. Extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem., 1965, V, 83-91.
41. Akashi, S.; Saitoh, S.-I.; Wakabayashi, Y.; Kikuchi, T.; Takamura, N.; Nagai, Y., Kusumoto, Y.; Fukase, K.; Kusumoto, S.; Adachi, Y.; Kosugi, A.; Miyake, K. Lipopolysaccharide interaction with cell surface toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med., 2003, 198, 1035-42.
42. Belay, A. Spirulina (Arthrospira): Production and quality assurance. In: Gershwin ME, Belay A.eds. Spirulina in human nutrition and health. New York: CRC Press, 2008, pp. 1-25.
43. Akao, Y.; Ebihara, T.; Masuda, H.; Saeki, Y.; Akazawa, T.; Hazeki, O.; Matsumoto, M.; Seya, T. Enhancement of antitumor natural killer cell activation by orally administered Spirulina extract in mice. Cancer Sci., 2009, 100, 1494-501.
44. Martin-Orozco, N.; Muranski, P.; Chung, Y.; Yang, X. O.; Yamazaki, T.; Lu, S.; Hwu, P.; Restifo, N. P.; Overwijk, W. W.; Dong, C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 2009, 31, 787-98.
45. Langowski, J. L.; Zhang, X.; Wu, L.; Mattson, J. D.; Chen, T.; Smith, C.; McClanahan, T.; Kastelein, R. A.; Oft, M. IL-23 promotes tumour incidence and growth. Nature, 2006, 442, 461-5.
46. Blotnick, S.; Peoples, G. E.; Freeman, M. R.; Eberlein, T. J.; Klagsbrun, M. T lymphocytes synthesize and export heparinbinding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: Differential production and release by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA, 1994, 91, 2890-4.
47. Miyoshi, E.; Higashiyama, S.; Nakagawa, T.; Hayashi, N.; Taniguchi, N. Membrane-anchored heparin-binding epidermal growth factor- like growth factor acts as a tumor survival factor in a hepatoma cell line. J. Biol. Chem., 1997, 272, 14349-55.
48. Tartour, E.; Fossiez, F.; Joyeux, I.; Galinha, A.; Gey, A.; Claret, E.; Sastre-Garau, X.; Couturier, J.; Mosseri, V.; Vives, V., Banchereau, J.; Fridman, W. H.; Wijdenes, J.; Lebecque, S.; Sautès-Fridman, C. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res., 1999, 59, 3698-704.
49. Benchetrit, F.; Ciree, A.; Vives, V.; Warnier, G.; Gey, A.; Sautès-Fridman, C.; Fossiez, F.; Haicheur, N.; Fridman, W. H.; Tartour, E. Interleukin-17 inhibits tumor cell growth by means of a T-celldependent mechanism. Blood, 2002, 99, 2114-21.
50. Lewis, C. E.; Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res., 2006, 66, 605-12.
51. Numasaki, M.; Watanabe, M.; Suzuki, T.; Takahashi, H.; Nakamura, A.; McAllister, F.; Hishinuma, T.; Goto, J.; Lotze, M. T.; Kolls, J. K.; Sasaki, H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol., 2005, 175, 6177-89.
52. Miyahara, Y.; Odunsi, K.; Chen, W.; Peng, G.; Matsuzaki, J.; Wang, R.-F. Generation and regulation of human CD4+ IL-17- producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. USA, 2008, 105, 15505-10.
53. Wang, L.; Yi, T.; Kortylewski, M.; Pardoll, D. M.; Zeng, D.; Yu, H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med., 2009, 206, 1457-64.
54. Shimizu, J.; Yamazaki, S.; Sakaguchi, S. Induction of tumor immunity by removing CD25+ CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immunol., 1999, 163, 5211-18.
55. Nam, J.-S.; Terabe, M.; Kang, M.-J.; Chae, H.; Voong, N.; Yang, Y.-A.; Laurence, A.; Michalowska, A., Mamura, M., Lonning, S.; Berzofsky, J. A.; Wakefield, L. M. Transforming growth factor?? subverts the immune system into directly promoting tumor growth through interleukin 17. Cancer Res., 2008, 68, 3915-23.
56. Li, M. O.; Wan, Y. Y.; Flavell, R. A. T cell-produced transforming growth factor-??1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity, 2007, 26, 579-91.
57. Laurence, A.; Tato, C. M.; Davidson, T. S.; Kanno, Y.; Chen, Z.; Yao, Z.; Blank, R. B.; Meylan, F., Siegel, R.; Hennighausen, L.; Shevach, E. M., O'Shea, J. J. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 2007, 26, 371-81.
58. Marks, B. R.; Nowyhed, H. N.; Choi, J.-Y.; Poholek, A. C.; Odegard, J. M. Flavell, R. A.; Craft, J. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat. Immunol., 2009, 10, 1125-32.
59. Bettelli, E.; Carrier, Y.; Gao, W.; Korn, T.; Strom, T. B.; Oukka, M.; Weiner, H. L.; Kuchroo, V. K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006, 441, 235-8.
60. Koenen, H. J. P. M.; Smeets, R. L.; Vink, P. M.; van Rijssen, E.; Boots, A. M. H.; Joosten, I. Human CD25high Foxp3pos regulatory T-cells differentiate into IL-17 producing cells. Blood, 2008, 112, 2340-52.
61. Elias, K. M.; Laurence, A.; Davidson, T. S.; Stephens, G.; Kanno, Y.; Shevach, E. M.; O'Shea, J. J. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood, 2008, 111,1013-20.
62. Mucida, D.; Park, Y.; Kim, G.; Turovskaya, O.; Scott, I.; Kronenberg, M.; Cheroutre, H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science, 2007, 317, 256-60.
63. Collison, L. W.; Workman, C. J.; Kuo, T. T.; Boyd, K.; Wang, Y.; Vignali, K. M.; Cross, R.; Sehy, D.; Blumberg, R. S.; Vignali, D. A. A. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 2007, 450, 566-9.
64. Lee, Y. K; Turner, H.; Maynard, C. L.; Oliver, J. R.; Chen, D.; Elson, C. O.; Weaver, C. T. Late developmental plasticity in the T helper 17 lineage. Immunity, 2009, 30, 92-107.
65. Nembrini, C.; Marsland, B. J.; Kopf, M. IL-17-producing T cells in lung immunity and inflammation. J. Allergy Clin. Immunol., 2009, 123, 986-94.
66. Schnyder-Candrian, S.; Togbe, D.; Couillin, I.; Mercier, I.; Brombacher, F.; Quesniaux, V.; Fossiez, F.; Ryffel, B.; Schnyder, B. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med., 2006, 203, 2715-25.
67. Luger, D.; Silver, P. B.; Tang, J.; Cua, D.; Chen, Z.; Iwakura, Y.; Bowman, E. P.; Sgambellone, N. M.; Chan, C.-C.; Caspi, R. R. Ei ther a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med., 2008, 205, 799-810.
68. O'Conner Jr, W.; Kamanaka, M.; Booth, C. J.; Town, T.; Nakae, S.; Iwakura, Y.; Kolls, J. K.; Flavell, R. A. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol., 2009, 10, 603-9.
69. Abdollahi-Roodsaz, S.; Joosten, L. A. B.; Koenders, M. I.; Devesa, I.; Roelofs, M. F.; Radstake, T. R. D. J.; Heuvelmans-Jacobs, M.; Akira, S.; Nicklin, M. J. H.; Ribeiro-Dias, F.; van den Berg, W. B. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest., 2008, 118, 205-16.
70. Marta, M.; Andersson, Å.; Lsaksson, M.; Kämpe, O.; Lobell, A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol., 2008, 38, 565-75.
71. Jin, J.-J.; Kim, H,-D.; Maxwell, J. A.; Li, L.; Fukuchi, K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflamm., 2008, 5, 23.
72. Rabinovich, G. A.; Toscano, M. A. Tuning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol.; 2009, 9, 338-52.
73. Toscano, M. A.; Bianco, G. A.; Ilarregui, J. M.; Croci, D. O.; Correale, J.; Hernandez, J. D.; Zwrner, N. W.; Poiirier, F.; Riley, E. M.; Baum, L. G.; Rabinovich, G. A. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol., 2007, 8, 825-34.
74. Seki, M.; Oomizu, S.; Sakata, K. M.; Sakata, A.; Arikawa, T.; Watanabe, K.; Ito, K.; Takseshita, K.; Niki, T.; Saita, N.; Nishi, N.; Yamauchi, A.; Katoh, S.; Matsukawa, A.; Kuchroo, V.; Hirashima, M. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol., 2008, 127, 78-88.
75. Katoh, S.; Ishii, N.; Nobumoto, A.; Takeshita, K.; Dai, S. Y.; Shinonaga, R.; Niki, T.; Tominaga, A.; Yamauchi, A.; Hirashima, M. Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am. J. Respir. Crit. Care Med., 2007, 176, 27-35.
76. Kubach, J.; Lutter, P.; Bopp, T.; Stoll, S.; Becker, C.; Huter, E.; Richter, C.; Weingarten, P.; Warger, T.; Knop, J.; Muller, S.; Wijdenes, J.; Schild, H.; Schmitt, E.; Jonuleit, H. Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood, 2007, 110, 1550-8.
77. Demotte, N.; Stroobant, V.; Courtoy, P. J.; Van Der Smissen, P.; Colau, D.; Luescher, I. F.; Hivroz, C.; Nicaise, J.; Squifflet, J.L.; Mourad, M; Godelaine, D.; Boon, T.; van der Bruggen, P. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity, 2008, 28, 414-24.
78. Nagahara, K.; Arikawa, T.; Oomizu, S.; Kontani, K.; Nobumoto, A.; Tateno, H.; Watanabe, K.; Niki, T.; Katoh, S.; Miyake, M; Nagahata, S.; Hirabayashi, J.; Kuchroo, V. R.; Yamauchi, A.; Hirashima, M. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9- Tim-3 interactions. J. Immunol., 2008, 181, 7660-9.
79. Parish, C. R. The role of heparan sulphate in inflammation. Nat. Rev. Immunol., 2006, 6, 633-43.
80. Wang, L.; Fuster, M.; Sriramarao, P.; Esko, J. D. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokinemediated neutrophil trafficking during inflammatory responses. Nat. Immunol., 2005, 6, 902-910.
81. Butler, L. M.; Rainger, G. Ed.; Nash, G. B. A role for the endothelial glycosaminoglycan hyluronan in neutrophil recruitment by endothelial cells cultured for prolonged periods. Exp. Cell. Res., 2009, 315, 3433-41.
82. Freeman, C.; Liu, L.; Banwell, M. G.; Brown, K. J.; Bezos, A.; Ferro, V.; Parish, C.R. Use of sulfated linked cyclitols as heparan sulfate mimetics to orobe the heparin/heparan sulfate binding specificity of proteins. J. Biol. Chem., 2005, 280, 8842-9.
83. Ellyard, J. I.; Simson, L.; Bezos, A.; Johnston, K.; Freeman, C.; Parish, C. R. Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. J. Biol. Chem., 2007, 282, 15238-47.
84. Kharabi Masouleh, B.; Ten Dam, G. B.; Wild, M. K.; Seelige, R.; van der Vlag, J.; Rops, A. L., Echtermeyer, F. G.; Vestweber, D.; van Kuppevelt, T. H.; Kiesel, L.; Götte, M. Role of the heparan sulfate proteoglycan-1 (CD138) in delayed-type hypersensitivity. J. Immunol., 2009, 182, 4985-93.
85. Round, J. L.; Mazmanian, S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol., 2009, 9, 313-23.
86. Mazmanian, S. K.; Round, J. L.; Kasper, D. L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature, 2008, 453, 620-5.